57 related articles for article (PubMed ID: 17973908)
1. Immunohistochemical analysis of receptor tyrosine kinase signal transduction activity in chordoma.
Fasig JH; Dupont WD; LaFleur BJ; Olson SJ; Cates JM
Neuropathol Appl Neurobiol; 2008 Feb; 34(1):95-104. PubMed ID: 17973908
[TBL] [Abstract][Full Text] [Related]
2. The emerging role of receptor tyrosine kinase phase separation in cancer.
Lin CC; Suen KM; Lidster J; Ladbury JE
Trends Cell Biol; 2024 May; 34(5):371-379. PubMed ID: 37777392
[TBL] [Abstract][Full Text] [Related]
3. Analysis of receptor tyrosine kinases (RTKs) and downstream pathways in chordomas.
Tamborini E; Virdis E; Negri T; Orsenigo M; Brich S; Conca E; Gronchi A; Stacchiotti S; Manenti G; Casali PG; Pierotti MA; Pilotti S
Neuro Oncol; 2010 Aug; 12(8):776-89. PubMed ID: 20164240
[TBL] [Abstract][Full Text] [Related]
4. The role of epidermal growth factor receptor in chordoma pathogenesis: a potential therapeutic target.
Shalaby A; Presneau N; Ye H; Halai D; Berisha F; Idowu B; Leithner A; Liegl B; Briggs TR; Bacsi K; Kindblom LG; Athanasou N; Amary MF; Hogendoorn PC; Tirabosco R; Flanagan AM
J Pathol; 2011 Feb; 223(3):336-46. PubMed ID: 21171079
[TBL] [Abstract][Full Text] [Related]
5. Response to erlotinib in a patient with treatment refractory chordoma.
Singhal N; Kotasek D; Parnis FX
Anticancer Drugs; 2009 Nov; 20(10):953-5. PubMed ID: 19730087
[TBL] [Abstract][Full Text] [Related]
6. Response to imatinib plus sirolimus in advanced chordoma.
Stacchiotti S; Marrari A; Tamborini E; Palassini E; Virdis E; Messina A; Crippa F; Morosi C; Gronchi A; Pilotti S; Casali PG
Ann Oncol; 2009 Nov; 20(11):1886-94. PubMed ID: 19570961
[TBL] [Abstract][Full Text] [Related]
7. Sacral chordoma: 40-year experience at a major cancer center.
York JE; Kaczaraj A; Abi-Said D; Fuller GN; Skibber JM; Janjan NA; Gokaslan ZL
Neurosurgery; 1999 Jan; 44(1):74-9; discussion 79-80. PubMed ID: 9894966
[TBL] [Abstract][Full Text] [Related]
8. Integrated Molecular and Histological Insights for Targeted Therapies in Mesenchymal Sinonasal Tract Tumors.
Hoch CC; Knoedler L; Knoedler S; Bashiri Dezfouli A; Schmidl B; Trill A; Douglas JE; Adappa ND; Stögbauer F; Wollenberg B
Curr Oncol Rep; 2024 Mar; 26(3):272-291. PubMed ID: 38376625
[TBL] [Abstract][Full Text] [Related]
9. A chronicle review of new techniques that facilitate the understanding and development of optimal individualized therapeutic strategies for chordoma.
Zhao C; Tan T; Zhang E; Wang T; Gong H; Jia Q; Liu T; Yang X; Zhao J; Wu Z; Wei H; Xiao J; Yang C
Front Oncol; 2022; 12():1029670. PubMed ID: 36465398
[TBL] [Abstract][Full Text] [Related]
10. Research hotspots and trends of chordoma: A bibliometric analysis.
Gao J; Huang R; Yin H; Song D; Meng T
Front Oncol; 2022; 12():946597. PubMed ID: 36185236
[TBL] [Abstract][Full Text] [Related]
11. Multivariate Analysis and Validation of the Prognostic Factors for Skull Base Chordoma.
Teng C; Yang Q; Xiong Z; Ye N; Li X
Front Surg; 2021; 8():764329. PubMed ID: 34888345
[No Abstract] [Full Text] [Related]
12. AZD8055 enhances in vivo efficacy of afatinib in chordomas.
Zhao T; Siu IM; Williamson T; Zhang H; Ji C; Burger PC; Connis N; Ruzevick J; Xia M; Cottone L; Flanagan AM; Hann CL; Gallia GL
J Pathol; 2021 Sep; 255(1):72-83. PubMed ID: 34124783
[TBL] [Abstract][Full Text] [Related]
13. LncRNA and mRNA expression profiles reveal the potential roles of lncRNA contributing to regulating dural penetration in clival chordoma.
Bai J; Zhai Y; Wang S; Li M; Zhang S; Li C; Gui S; Li Q; Zhang Y
Aging (Albany NY); 2020 Jun; 12(11):10809-10826. PubMed ID: 32533822
[TBL] [Abstract][Full Text] [Related]
14. Chordoma: A Case Report and Review of Literature.
Noor A; Bindal P; Ramirez M; Vredenburgh J
Am J Case Rep; 2020 Jan; 21():e918927. PubMed ID: 31969553
[TBL] [Abstract][Full Text] [Related]
15. Active receptor tyrosine kinases, but not Brachyury, are sufficient to trigger chordoma in zebrafish.
D'Agati G; Cabello EM; Frontzek K; Rushing EJ; Klemm R; Robinson MD; White RM; Mosimann C; Burger A
Dis Model Mech; 2019 Jul; 12(7):. PubMed ID: 31221659
[TBL] [Abstract][Full Text] [Related]
16. Microenvironmental Targets in Sarcoma.
Ehnman M; Larsson O
Front Oncol; 2015; 5():248. PubMed ID: 26583076
[TBL] [Abstract][Full Text] [Related]
17. The molecular aspects of chordoma.
Gulluoglu S; Turksoy O; Kuskucu A; Ture U; Bayrak OF
Neurosurg Rev; 2016 Apr; 39(2):185-96; discussion 196. PubMed ID: 26363792
[TBL] [Abstract][Full Text] [Related]
18. Novel targeted therapies in chordoma: an update.
Di Maio S; Yip S; Al Zhrani GA; Alotaibi FE; Al Turki A; Kong E; Rostomily RC
Ther Clin Risk Manag; 2015; 11():873-83. PubMed ID: 26097380
[TBL] [Abstract][Full Text] [Related]
19. Immunohistochemical expression of receptor tyrosine kinase PDGFR-α, c-Met, and EGFR in skull base chordoma.
Akhavan-Sigari R; Abili M; Gaab MR; Rohde V; Zafar N; Emami P; Ostertag H
Neurosurg Rev; 2015 Jan; 38(1):89-98; discussion 98-9. PubMed ID: 25323095
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET.
Zhang Y; Schiff D; Park D; Abounader R
PLoS One; 2014; 9(3):e91546. PubMed ID: 24621885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
